Results 121 to 130 of about 8,451 (198)

Mepolizumab: Which condition benefits more: Nasal polyps or eosinophilic asthma? Mepolizumab: Hangi durum daha fazla fayda sağlar: Burun polipleri mi, eozinofilik astım mı?

Mepolizumab: Which condition benefits more: Nasal polyps or eosinophilic asthma? Introduction: The negative effects of eosinophilic severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) on quality of life are well known.
PAÇACI ÇETİN, GÜLDEN, YILMAZ, İNSU, AÇAR, ELİF, AKTAŞ YAPICI, ELİF, TÜRK, MURAT, ARSLAN, BAHAR, BOZKURT YILMAZ, HATİCE EYLÜL, ŞEKER, SERHAT, KÖYLÜCE, SERPİL   +8 more
core   +1 more source

Mepolizumab in Pediatric Severe Eosinophilic Asthma: A Review of Efficacy, Safety, and Clinical Applications. [PDF]

J Inflamm Res
Bajeli M, Corsello A, Foti Randazzese S, Marseglia A, D'Agostino P, Rossi CM, Marseglia GL, Licari A.   +7 more
europepmc   +1 more source

Mepolizumab efficacy in chronic obstructive pulmonary disease: insights from longitudinal patterns of blood eosinophil counts and their variability across 3 clinical trials. [PDF]

Am J Respir Crit Care Med
Criner GJ, Watz H, Han MK, Martinez FJ, Gould S, Min J, Biswas A, Kolterer S, Singh D.   +8 more
europepmc   +1 more source

Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis

International audienceBACKGROUND: Eosinophilic granulomatosis with polyangiitis (EGPA) is a vasculitis characterized by eosinophilic inflammation. Benralizumab, a monoclonal antibody against the interleukin-5α receptor expressed on eosinophils, may be an
Jison, Maria, Wechsler, Michael M.E., Jayne, David, Jackson, David J., Shavit, Anat, Walz, Bastian, Wechsler, Michael E., Merkel, Peter PA, Jackson, David J, Mccrae, Christopher, Jackson, David, Nair, Parameswaran, Börjesson Sjö, Lena, Jayne, David R.W., Jayne, David R.W.David, Fan, Ying, Wechsler, Michael, Roufosse, Florence, Merkel, Peter, Merkel, Peter A., Walton, Claire, Bourdin, Arnaud, Sjö, Lena Börjesson, Necander, Sofia, Fan, Yingying, Terrier, Benjamin   +25 more
core   +1 more source

Cost-effectiveness of mepolizumab for severe eosinophilic asthma in China

To evaluate the economic value of mepolizumab as an add-on therapy to the standard of care (SoC) for patients with severe eosinophilic asthma in China.
Wang Zhen (4615225), Li Ying (136738), Ma Wenbin (11934811), Xiong Chaogang (18144183), Zhao Yuan (547890), Lei Qian (292302), Gu Xin (17475110), Zhang Shengjie (18144189), Feng Weiyi (18144192), An Mengna (18144186), Zhang Xin (6264812)   +10 more
core   +1 more source

Refractory Hypereosinophilic Syndrome With Clonal T-Cell Receptor Rearrangement Treated With JAK Inhibition Following Incomplete Response to IL-5 Blockade. [PDF]

Case Rep Hematol
McKaughan KW, Truong PV, Bongers G.
europepmc   +1 more source

Three-year sustained remission with mepolizumab in a rare eosinophilic disease: idiopathic chronic eosinophilic pneumonia. [PDF]

Eur Clin Respir J
Akten HS, Inan S, Galata Z, Ozgur S, Ozeke Y, Gumusburun R, Demiroglu G, Goksel O.   +7 more
europepmc   +1 more source

Prioritizing efficacy over convenience. [PDF]

Am J Respir Crit Care Med
Siddiqui S, Brooks L, Menzies-Gow A, Akuthota P.   +3 more
europepmc   +1 more source

A Case Report of Refractory Allergic Bronchopulmonary Aspergillosis: The Art of Selection, Discontinuation and Switching Biologics. [PDF]

J Inflamm Res
Li Y, Yang S, Ren S, Cao P, Zhang Z, Zhang Y.   +5 more
europepmc   +1 more source

Effectiveness of mepolizumab on mucus plugs and clinical outcomes in severe eosinophilic asthma with and without coexisting bronchiectasis: a prospective pilot study. [PDF]

ERJ Open Res
Campisi R, Nolasco S, Mancuso M, Nardo AA, Intravaia R, Pelaia C, Vancheri C, Crimi N, Crimi C.   +8 more
europepmc   +1 more source